Increasing evidence that the risks of rhAPC may outweigh its benefits
- PMID: 17325833
- DOI: 10.1007/s00134-007-0556-8
Increasing evidence that the risks of rhAPC may outweigh its benefits
Comment in
-
Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.Intensive Care Med. 2007 Aug;33(8):1487-8; author reply 1489-91. doi: 10.1007/s00134-007-0709-9. Epub 2007 Jun 12. Intensive Care Med. 2007. PMID: 17563878 No abstract available.
-
Is there increasing evidence that the risks of rhAPC may outweigh its benefits?Intensive Care Med. 2007 Aug;33(8):1485-6; author reply 1489. doi: 10.1007/s00134-007-0707-y. Epub 2007 Jun 12. Intensive Care Med. 2007. PMID: 17563880 No abstract available.
Comment on
-
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.Intensive Care Med. 2007 Mar;33(3):426-34. doi: 10.1007/s00134-007-0554-x. Epub 2007 Feb 15. Intensive Care Med. 2007. PMID: 17325836
-
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.Intensive Care Med. 2007 Mar;33(3):517-23. doi: 10.1007/s00134-007-0555-9. Epub 2007 Feb 15. Intensive Care Med. 2007. PMID: 17325837
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
